IMR Press / FBL / Volume 16 / Issue 5 / DOI: 10.2741/3812

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Inflammatory markers and cardiovascular risk in the metabolic syndrome
Show Less
1 2nd Department of Internal Medicine, University Medical Center of the Johannes, Gutenberg-University Mainz, Germany

Academic Editor: Marius Troseid

Front. Biosci. (Landmark Ed) 2011, 16(5), 1663–1674;
Published: 1 January 2011
(This article belongs to the Special Issue The metabolic syndrome- role of inflammation and adipose tissue)

Elevated blood glucose, obesity, high blood pressure, elevated triglycerides and low high density lipoprotein (HDL) cholesterol are well accepted risk factors in the development of coronary artery disease. Clustering of at least three of these factors in an individual is defined as metabolic syndrome (MetS). Obesity is a central pathological mechanism in the disease and it is expected that the incidence of this condition will increase dramatically within the next years. The visceral adipose tissue is not only an energy depot but also an endocrine organ which produces a large number of bioactive molecules, the so called adipokines. In the setting of obesity, the over-production of proinflammatory and pro-thrombotic adipokines is associated with insulin resistance. This mechanism represents the pathophysiological basis for the development of MetS. Inflammation has a central role in the pathogenesis of MetS and in mediating its impact on the development of cardiovascular disease. Knowledge of these mechanisms has relevance in the context of preventive and therapeutic strategies.

Back to top